Policy | March 13, 2024
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
‘Unmask Anemia’ aims to simplify assessment of iron deficiency anemia risk with an easy online self-test based on common signs and symptoms
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
The agreement sets terms under which POC will manufacture the product or receive royalties
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination
Subscribe To Our Newsletter & Stay Updated
